Bli medlem
Bli medlem

Du är här

2017-02-07

Bactiguard Holding AB (publ): Bactiguard enters new therapeutic area through license agreement

Bactiguard and Smartwise Sweden AB (Smartwise) have entered into a
joint development project for advanced, Bactiguard-coated vascular
injection catheters. At the same time, a license agreement has been
signed. Smartwise will pay USD 2.5 million, for the exclusive and
global right to the Bactiguard technology for this application,
payable in 2017, and followed by royalty payments once the products
are commercialized.

"We are very excited about the partnership with Smartwise, as it
expands our technology to a completely new application area.
Delivering drugs and other therapies to vital organs is a complicated
and delicate form of intervention, where the anti-infective and
tissue friendly properties of the Bactiguard coating will reduce
risks and increase patient safety", says Cecilia Edström, SVP Sales
and New Business.

"The advanced injection technology we are developing has the potential
to become a major breakthrough in delivering therapies to targeted
and critical areas of the body, such as the heart and the brain. By
applying the Bactiguard coating to our micro catheters, we can reduce
the risk of infections, thrombosis and allergic reactions for
critically ill patients", says Jonathan Clarke, CEO Smartwise.

"In addition, the unique combination of the anti-thrombotic and
electrical conductive properties of the coating allows us to further
develop our catheter technology to access the most remote parts of
the brain. This will add significant value to our technology as we
are entering commercial negotiations with third parties", Jonathan
Clarke continues.

The coating process for the micro catheters developed by Smartwise
will be developed by Bactiguard. Smartwise will be responsible for
the certification and registration process and for conducting
clinical trials.

Once Smartwise starts receiving revenues from its customers,
Bactiguard will receive royalties as a percentage of third party
sales. The product is currently in the pre-clinical development
phase, and it is expected that it will take some three to five years
until the product will be approved for clinical use.

By entering the agreement with Smartwise, Bactiguard expands its
license business to comprise three different therapeutic areas, Foley
catheters, orthopaedic implants and now, advanced transvascular
injection catheters.

Since 1995, Bactiguard has a successful licensing agreement with C.R
Bard, Inc (Bard) in the US. As a result of this successful
partnership, more than 160 million Bactiguard coated Foley-catheters
have been sold to date, primarily in the US and Japan.

In 2015, a license agreement for Bactiguard coated orthopaedic trauma
implants, covering the Asean region, was initiated with Vigilenz
Medical Devices. Clinical evaluations are ongoing and the
anti-infective trauma implants are expected to reach the market later
this year.

Through the new development project and license agreement with
Smartwise, Bactiguard takes a step towards entering another
interesting therapeutic area, whereby drugs and other interventional
therapies can be targeted and delivered to specific organs, such as
the heart, lungs and the brain. The full potential of this
application is yet unexplored, but pharmaceutical companies,
researchers and clinicians see a great benefit in being able to
deliver high dose, locally targeted therapies to damaged tissue,
following for example stroke and heart attack, or to tumors for high
dose chemotherapy.

This information is information that Bactiguard Holding AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication, through the agency of
the contact person set out below 2017-02-07, at 08.00

For further information, please contact:

Cecilia Edström, SVP Sales & New Business, cell phone: +46 72 226 23
28

About Smartwise

Smartwise is a company active in developing and manufacturing
transvascular catheter technologies, including a micro catheter
system for drug delivery. The company was founded in 2015, based on
an innovation by Professor Staffan Holmin, Karolinska University
Hospital, and started as a seed investment within Karolinska
Innovation AB (KIAB). The company is privately owned by a group of
investors, including Christian Kinch and Thomas von Koch.

Jonathan Clarke is a physician scientist with dual board
certifications in Internal Medicine and Cardiology with an MD from
Harvard Medical School. He completed his Internal Medicine training
at NYPH-Weil Cornell Medical Center and his cardiology fellowship at
Massachusetts General Hospital. He has also been active as a research
fellow at the Karolinska Institute in Stockholm and joined Smartwise
as its CEO in 2015.

About Bactiguard

Bactiguard is a Swedish medtech company with a global presence,
offering a solution that prevents healthcare associated infections
caused by medical devices. By preventing infections, we contribute to
a reduced use of antibiotics and the spread of multi-resistant
bacteria, which is a growing problem worldwide. We save lives,
increase patient safety and significantly reduce the cost for the
healthcare and society. Our technology is well-proven, safe and
tissue friendly and consist of a thin layer of noble metals that
prevents bacterial growth. The coating can be applied on almost all
medical devices. Bactiguard-coated urinary catheters are market
leading in the US and Japan and the company has also its own product
portfolio consisting of Foley catheters, central venous catheters and
endotracheal tubes. Bactiguard is a growth company, focused on
markets in Europe, Middle East, Asia and Latin America. The company
has about 60 employees worldwide, mainly at the headquarters in
Stockholm and the production facility in Malaysia and is listed on
Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com

-----------------------------------------------------------
http://news.cision.com/bactiguard-holding-ab--publ-/r/bactiguard-enters-...
http://mb.cision.com/Main/9686/2181838/624549.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.